Ring Nitrogen Is Shared By The Cyclos Of The Bicyclo Ring System Patents (Class 514/413)
-
Patent number: 7776791Abstract: The invention relates to novel N-heterocyclylphenyl-substituted cyclic ketoenols of the formula (I) in which CKE, W, X, Y and Z are as defined in the disclosure, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or microbicides. The invention further relates to selective herbicidal compositions comprising firstly the N-heterocyclylphenyl-substituted cyclic ketoenols and secondly a compound which improves crop plant tolerance.Type: GrantFiled: June 7, 2004Date of Patent: August 17, 2010Assignee: Bayer CropScience AGInventors: Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Stefan Lehr, Klaus Kunz, Jörg Konze, Olga Malsam, Mark Wilhelm Drewes, Dieter Feucht, Karl-Heinz Kuck, Ulrike Wachendorff-Neumann, Wahed Ahmed Moradi, Guido Bojack, Thomas Auler, Martin Hills, Heinz Kehne
-
Patent number: 7776880Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.Type: GrantFiled: March 19, 2009Date of Patent: August 17, 2010Assignee: sanofi-aventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Maria-Carmen Renones
-
Patent number: 7776876Abstract: Embodiments of this invention provide methods for thereapeutic use of cyclic G-2-Allyl Proline to treat disorders of dopaminergic neurons, including Parkinson's disease. Cyclic G-2Allyl P is neuroprotective and has utility as a therapeutic agent for treatment of diseases and other conditions characterised by degeneration and/or death of dopaminergic neurons and the adverse symptoms of such degeneration and/or death. Such symptoms include loss of cognition and motor function. Compounds are also useful for manufacture of medicaments including tablets, capsules and injectable solutions that are useful for treatment of such conditions.Type: GrantFiled: April 7, 2006Date of Patent: August 17, 2010Assignee: Neuren Pharmaceuticals, Ltd.Inventors: Margaret Anne Brimble, Jian Guan
-
Publication number: 20100190688Abstract: Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided.Type: ApplicationFiled: July 12, 2005Publication date: July 29, 2010Inventors: Bin Chao, Thomas L. Deckwerth, Paul S. Furth, Steven D. Linton, Alfred P. Spada, Brett R. Ullman, Michael I. Weinhouse
-
Patent number: 7763635Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.Type: GrantFiled: August 17, 2007Date of Patent: July 27, 2010Assignee: Supermus Pharmaceuticals, Inc.Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
-
Patent number: 7759359Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.Type: GrantFiled: August 17, 2007Date of Patent: July 20, 2010Assignee: Supernus Pharmaceuticals, Inc.Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
-
Publication number: 20100173960Abstract: The invention relates generally to novel compositions and methods comprising one or more cyclohexanehexol and one or more NSAID. The compositions and methods provide beneficial effects in the treatment and prevention of diseases involving a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence, in particular neurodegenerative diseases.Type: ApplicationFiled: September 20, 2007Publication date: July 8, 2010Inventors: Antonio Cruz, Carl Damiani
-
Publication number: 20100173876Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.Type: ApplicationFiled: July 30, 2009Publication date: July 8, 2010Applicant: The Board of Regents of the University of Texas SystemInventors: Lenard M. Lichtenberger, Shiqiang Tian
-
Publication number: 20100158993Abstract: Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alcoholic and alcohol-free topical compositions comprising an NSAID prodrug are also disclosed. The compositions are particularly useful for the treatment of pseudofolliculitis barbae.Type: ApplicationFiled: December 21, 2009Publication date: June 24, 2010Applicant: ISW Group, Inc.Inventors: Monique Spann-Wade, Anthony Ward
-
Publication number: 20100130580Abstract: The present invention provides compositions comprising a low dose amount of an ophthalmic NSAID for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye and safe for chronic use.Type: ApplicationFiled: October 19, 2009Publication date: May 27, 2010Applicant: Aciex Therapeutics, Inc.Inventors: George W. Ousler, III, Matthew J. Chapin, Mark B. Abelson
-
Patent number: 7723382Abstract: The present invention refers to a process for preparing a compound of general formula (A), as reported in the description, wherein R is a radical of a drug and R1-R12 are hydrogen or alkyl groups, m, n, o, q, r and s are each independently an integer from 0 to 6, and p is 0 or 1, and X is O, S, SO, SO2, NR13 or PR13 or an aryl, heteroaryl group, said process comprising reacting a compound of formula (B) R—COOZ (B) wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1-R12 and m, n, o, p, q, r, s are as defined above and Y is a suitable leaving group.Type: GrantFiled: August 6, 2003Date of Patent: May 25, 2010Assignee: Nicox S.A.Inventors: Piero del Soldato, Giancarlo Santus, Francesca Benedini
-
Publication number: 20100099730Abstract: The present invention relates to the use of annellated pyrrole compounds and in particular ML3000 (licofelone), salts or derivatives thereof, for cancer management, and in general to the use of a compound of Formula (I): wherein the variables have the meanings given in the present description, for the prevention and/or treatment of neoplasia, in particular neoplasia selected from the group consisting of papilloma, carcinoma, adenoma and adenocarcinoma, e.g. human airway or colorectal carcinoma, preferably fast-growing, multidrug resistant and/or COX-2 negative neoplasia. The invention further relates to pharmaceutical compositions for the aforesaid purposes, comprising annellated pyrrole compounds and in particular ML3000 (licofelone), optical isomers, salts or derivatives thereof, as well as to a method of treating and/or preventing neoplasia and/or restoring the ability to undergo apoptosis in a cell having lost the same.Type: ApplicationFiled: July 30, 2007Publication date: April 22, 2010Applicant: MERCKLE GMBHInventors: Stefan Laufer, Tiziana Guarnieri, Simona Tavolari, Vittorio Tomasi, Ernesto Palazzini, Miriam Barbanti
-
Publication number: 20100087503Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.Type: ApplicationFiled: September 1, 2009Publication date: April 8, 2010Applicant: ALLERGAN, INC.Inventors: Eldon Q. Farnes, Mayssa Attar, Rhett M. Schiffman, Chin-Ming Chang, Richard S. Graham, Devin F. Welty
-
Publication number: 20100081631Abstract: Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to affliction with a disease or condition selected from an esophageal ulcer, alcohol gastropathy, a duodenal ulcer, a gastric ulcer, non-steroidal anti-inflammatory drug-induced gastroenteropathy and intestinal ischemia. Such administration results in treating or preventing the disease or condition.Type: ApplicationFiled: December 11, 2007Publication date: April 1, 2010Inventors: Guang Liang Jiang, Wha Bin Im, Larry A. Wheeler
-
Publication number: 20100081700Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: ApplicationFiled: September 24, 2009Publication date: April 1, 2010Inventors: Alan Xiangdong Wang, Ramkumar Rajamani, Paul Michael Scola
-
Patent number: 7674794Abstract: Compounds of formula (I) wherein n is 0, 1, or 2; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.Type: GrantFiled: November 15, 2006Date of Patent: March 9, 2010Assignee: Abbott LaboratoriesInventors: Jianguo Ji, Tao Li
-
Publication number: 20100035916Abstract: The invention relates to compounds of the general formula (I): Wherein R, m, n and o are as defined herein. The invention also relates to a method for preparing the same and to the application in therapy.Type: ApplicationFiled: August 4, 2009Publication date: February 11, 2010Applicant: SANOFI-AVENTISInventors: Omar BEN AYAD, Odile LECLERC, Alistair LOCHEAD, Mourad SAADY, Franck SLOWINSKI, Julien VACHE
-
Publication number: 20100016402Abstract: This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation.Type: ApplicationFiled: June 12, 2009Publication date: January 21, 2010Inventors: Roger Whiting, Ramachandran Thirucote
-
Publication number: 20100010046Abstract: Parenteral formulations comprising ketorolac, and a compound of formula II wherein R is hydrogen or lower alkyl. Such formulations are used for the treatment and prevention of pain.Type: ApplicationFiled: June 8, 2007Publication date: January 14, 2010Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Mark G. Currie, Daniel P. Zimmer
-
Publication number: 20100004189Abstract: Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator.Type: ApplicationFiled: May 1, 2009Publication date: January 7, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20090326034Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.Type: ApplicationFiled: March 2, 2009Publication date: December 31, 2009Applicant: ALLERGAN, INC.Inventors: Eldon Q. Farnes, Mayssa Attar, Rhett M. Schiffman, Chin-Ming Chang, Richard S. Graham, Devin F. Welty
-
Publication number: 20090326035Abstract: Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions include a combination of a carrier component and a bioactive component which acts to prevent or reduce post-operative ileus. Such methods include administering atherapeutically effective amount of the composition directly to the serosal surfaces of the gastrointestinal and other visceral organs.Type: ApplicationFiled: September 8, 2009Publication date: December 31, 2009Inventors: Uri Herzberg, Scott Wadsworth, Kevin Cooper
-
Publication number: 20090275539Abstract: The present invention relates to novel compounds that are nuclear transcription factors (NTF) regulators. The present invention also provides methods for treating, preventing and/or reducing inflammation associated diseases by regulating NTF in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous, or cutaneous systems as well as tumoral and infective diseases employing said compounds.Type: ApplicationFiled: October 5, 2005Publication date: November 5, 2009Applicant: CTG PHARMA S.R.L.Inventor: Anna Sparatore
-
Patent number: 7612099Abstract: The invention is concerned with vinylogous acids derivatives of formula (I) wherein A and R1 to R6 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit chymase and can be used as medicaments.Type: GrantFiled: November 28, 2006Date of Patent: November 3, 2009Assignee: Hoffmann-La Roche Inc.Inventors: David Banner, Hans Hilpert, Bernd Kuhn, Harald Mauser
-
Publication number: 20090264493Abstract: A process for producing an aqueous solution of doripenem while decomposition of doripenem by heat is suppressed is found out. It was found out that decomposition of doripenem by heat can be suppressed by continuous heating an aqueous suspension of doripenem, and it was found out that an aqueous solution of doripenem can be produced.Type: ApplicationFiled: May 25, 2006Publication date: October 22, 2009Inventor: Hayao Nakanishi
-
Publication number: 20090263319Abstract: Methods and compositions are provided for reducing, treating or preventing postoperative pain or inflammation in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of ketorolac or pharmaceutically acceptable salt thereof to a target tissue site, wherein the drug depot releases an effective amount of ketorolac or pharmaceutically acceptable salt thereof over a period of 3 to 10 days.Type: ApplicationFiled: February 19, 2009Publication date: October 22, 2009Applicants: Warsaw Orthopedic, Inc., Medtronic Inc.Inventors: Amira Wohabrebbi, William F. McKay, Christopher M. Hobot, Keith R. Hildebrand, Edward Phillip McDonald
-
Publication number: 20090258899Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.Type: ApplicationFiled: March 19, 2009Publication date: October 15, 2009Applicant: SANOFI-AVENTISInventors: Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Florence MEDAISKO, Maria-Carmen RENONES
-
Publication number: 20090246273Abstract: The present invention provides for compositions and methods for accelerating the rate of delivery of ketorolac to the systemic circulation by sublingual spray administration under the tongue to provide a rapid response in the treatment of pain, especially acute pain associated with postoperative pain and migraine headache. Compositions of ketorolac formulated for sublingual delivery as liquid spray are provided. Also provided are methods of treatment and management of pain.Type: ApplicationFiled: March 25, 2009Publication date: October 1, 2009Inventor: Abeer M. Al-Ghananeem
-
Publication number: 20090227534Abstract: This invention refers to the pharmaceutical combinations of Ketorolac salts and B-complex; to the methods used to make said combinations; and particularly, to ketorolac and B-complex synergic combinations useful in the treatment of patients that suffer from moderate to severe pain and neuralgias in different body sites.Type: ApplicationFiled: April 10, 2007Publication date: September 10, 2009Applicant: LABORATORIOS SENOSITAN S.A. DE C.V.Inventors: Enrique Raul Garcia-Salgado Lopez, Gustavo Barranco Hernandez
-
Publication number: 20090227563Abstract: The present invention concerns boosting the activity of crop protection materials comprising active ingredients from the class of the phenyl-substituted cyclic ketoenols through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium salts and/or phosphonium salts and penetrants, the corresponding materials, processes for preparing them, and their use in crop protection.Type: ApplicationFiled: December 11, 2006Publication date: September 10, 2009Applicant: Bayer CropScience AGInventors: Reiner Fischer, Stefan Lehr, Dieter Feucht, Udo Bickers, Hans Philipp Huff, Erwin Hacker, Rainer Süssmann
-
Publication number: 20090221697Abstract: The present invention relates to macrolide conjugates of pyrrolizine and indolizine derivatives with macrocyclic antibiotics and derivatives thereof. The macrolide conjugates are potent inhibitors of 5-lipoxygenase and cyclooxygenase and are therefore suitable to treat disorders of the rheumatic type and to prevent allergically induced diseases. The macrolide conjugates have significantly enhanced potency and efficacy.Type: ApplicationFiled: July 26, 2006Publication date: September 3, 2009Applicant: MERCKLE GMBHInventors: Stefan Laufer, Wolfgang Albrecht, Michael Burnet, Hans-Jürgen Gutke
-
Publication number: 20090209610Abstract: The present invention relates to a new crystalline modification of 6-(4-chlorophenyl)-2,2-dmethyl-7-phenyl-2, S-dihydro-1H-pyrrolizin-S-ylacetic acid which is referred to as polymorph B. It has a peak in the solid state 13C-NMR spectrum (with adamantane as external reference standard; CH group d=29.45 ppm) in the range from 179.8 to 180.2 ppm and can be processed directly to a pharmaceutical formulation.Type: ApplicationFiled: March 20, 2006Publication date: August 20, 2009Applicant: Merckle GmgHInventors: Wolfgang Albrecht, Thomas Kammermeier, Hans-Gunter Striegel, Philipp Merckle, Stefan Laufer
-
Publication number: 20090203760Abstract: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.Type: ApplicationFiled: August 19, 2008Publication date: August 13, 2009Applicant: THE UNIVERSITY OF QUEENSLANDInventors: David FAIRLIE, Stephen Maxwell Taylor, Angela Monique Finch, Allan Wong
-
Publication number: 20090203759Abstract: The present invention relates to a pharmaceutical formulation comprising: a) one or more NO-releasing NSAID(s) of formula (I); b) one or more surfactants; c) a carbonyl scavenger compound selected from free acid forms, salts, carboxylic acid esters derivatives of a compound of formula (II) H2N—(CH2)m—(C6H4)—COOH??(II) wherein m=0-10; and d) optionally an oil or semi-solid fat and/or a short-chain alcohol.Type: ApplicationFiled: June 29, 2006Publication date: August 13, 2009Inventors: Ulla Gasslander, Christina Holmberg
-
Publication number: 20090191153Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: ApplicationFiled: December 3, 2008Publication date: July 30, 2009Inventors: Ying Sun, Deqiang Niu, Guoyou Xu, Yat Sun Or, Zhe Wang
-
Publication number: 20090180984Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: ApplicationFiled: December 12, 2008Publication date: July 16, 2009Inventors: Ying Sun, Yonghua Gai, Yat Sun Or, Zhe Wang
-
Publication number: 20090180983Abstract: The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: ApplicationFiled: November 26, 2008Publication date: July 16, 2009Inventors: Joel D. Moore, Yat Sun Or, Zhe Wang
-
Patent number: 7560483Abstract: The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.Type: GrantFiled: June 21, 2005Date of Patent: July 14, 2009Assignee: XenoPort, Inc.Inventors: Mark A. Gallop, Jia-Ning Xiang, Fenmei Yao, Laxminarayan Bhat, Cindy X. Zhou
-
Patent number: 7553836Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1a, R1b, R1c, Q, A, R3, W, D and R2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.Type: GrantFiled: February 5, 2007Date of Patent: June 30, 2009Assignee: Bristol-Myers Squibb CompanyInventor: Guohua Zhao
-
Publication number: 20090123480Abstract: The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.Type: ApplicationFiled: November 13, 2008Publication date: May 14, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Haiying Sun, Dongguang Qin, Zaneta Nikolovska-Coleska, Jianfeng Lu, Su Qiu, Yuefeng Peng, Qian Cai
-
Publication number: 20090117083Abstract: Immunotherapy comprises administration of an alkaloid at a dose sufficient to induce IL-2 production in dendritic cells in a patient. The alkaloid induces the production of IL-2 in dendritic cells. The alkaloids need not be naturally occurring, and may be synthetic analogues or derivatives of naturally occurring counterparts. Such analogues or derivatives are preferably pharmaceutically acceptable analogues, salts, isomers or derivatives as herein defined. However, preferred alkaloids are phytochemicals. Such phytochemicals may be isolated from natural sources or synthesised in vitro. Particularly preferred are alkaloids is selected from piperidine alkaloids; pyrrolin alkaloids; pyrrolidine alkaloids; pyrolizidine alkaloids: indolizidine alkaloids and nortropane alkaloids.Type: ApplicationFiled: January 21, 2005Publication date: May 7, 2009Applicant: M N L PHARMA LIMITEDInventors: Robert James Nash, Alison Ann Watson, Emma Louisa Evinson, Hadyn St. Pierre Parry
-
Publication number: 20090110755Abstract: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases.Type: ApplicationFiled: October 29, 2008Publication date: April 30, 2009Inventor: Alexander Mauskop
-
Publication number: 20090093510Abstract: The present invention relates to the use of nitric oxide releasing compounds for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.Type: ApplicationFiled: January 23, 2007Publication date: April 9, 2009Inventors: Emilio Clementi, Giulio Cossu, Silvia Brunelli, Ennio Ongini
-
Publication number: 20090093669Abstract: A method and apparatus for administering drugs through a dermal or mucosal layer such that the treatment device may be applied to the mammal for the transdermal or transmucosal administration of various drugs, pharmaceuticals, salts and prodrugs thereof is taught herein. The magnetic device has at least one magnet to provide an effective magnetic sphere of influence of the magnetic field at the desired site of action. The tissue-permeable drug formulation is positioned on the site of action and the magnetic device is positioned adjacent to tissue-permeable drug formulation wherein the magnetic sphere of influence of the magnetic field moves the drug through the dermal or mucosal layer by interaction with the magnetic moment (induced or permanent) of the drug sufficient to increase the movement of the drug beyond the movement caused by diffusion alone.Type: ApplicationFiled: October 3, 2008Publication date: April 9, 2009Inventors: WILLIAM A. FARONE, W. BRADLEY WORTHINGTON
-
Publication number: 20090088418Abstract: The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.Type: ApplicationFiled: September 30, 2008Publication date: April 2, 2009Applicant: CoMentis, Inc.Inventors: Jurg R. Pfister, Meenakshi S. Venkatraman, Xiaoming Zhang
-
Publication number: 20090069294Abstract: The present disclosure relates to XIAP inhibitor compounds of the formula I.Type: ApplicationFiled: June 6, 2006Publication date: March 12, 2009Inventors: Zhuoliang Chen, Mark G. Palermo, Sushil K. Sharma, Troy Smith, Christopher S. Straub, Run-Ming D. Wang, Yaping Wang, Leigh Zawel
-
Publication number: 20090062315Abstract: A pharmaceutical acceptable composition is provided. The composition comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a local anesthetic, and an antiviral drug.Type: ApplicationFiled: August 28, 2008Publication date: March 5, 2009Applicant: Yung Shin Pharmaceutical Industrial Co., Ltd.Inventors: Fangchen Lee, Hui-Ling Shieh, Chiung-Ju Tsai, Shin-Hong Jang
-
Publication number: 20090048270Abstract: Methods, compositions and devices for inhibiting neoproliferative changes in blood vessel walls or other anatomical structures. One or more compounds of Formula I or I-A set forth herein are administered systemically and/or locally to human or veterinary patients to deter or prevent unwanted proliferative changes in blood vessels or other anatomical structures. The invention may be used to deter or prevent stenosis or restenosis of arteries following angioplasty and/or stent placement. In one embodiment, there is provided an implantable stent or stent graft from which one or more compounds of the present invention will elute or otherwise be delivered into an affected blood vessel wall.Type: ApplicationFiled: October 30, 2003Publication date: February 19, 2009Inventors: Ralf Koehler, Heike Wulff, Joachim Hoyer, K. George Chandy
-
Publication number: 20090048159Abstract: A kit for treating a health condition in a mammal comprises a calreticulin protein and/or compound for inducing a translocation of a calreticulin protein to a cellular membrane in order to provoke an immunogenic apoptosis. The calreticulin protein may include any one or more of: endogenous calreticulin, recombinant calreticulin, and calreticulin in mimetic form. The endogenous form of calreticulin may include any one of: a plasma membrane calreticulin and an intracellular calreticulin.Type: ApplicationFiled: August 25, 2007Publication date: February 19, 2009Inventor: Michel Sarkis OBEID
-
Publication number: 20090041721Abstract: The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.Type: ApplicationFiled: August 9, 2007Publication date: February 12, 2009Inventors: Deqiang Niu, Yonghua Gai, Yat Sun Or, Zhe Wang